Dyne Therapeutics (NASDAQ:DYN) PT Raised to $43.00 at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) had its price objective hoisted by JPMorgan Chase & Co. from $39.00 to $43.00 in a report issued on Tuesday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer restated an outperform rating and set a $47.00 price objective on shares of Dyne Therapeutics in a report on Monday, May 6th. HC Wainwright boosted their price objective on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a buy rating in a report on Monday, May 20th. Chardan Capital lifted their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a buy rating in a research report on Tuesday, May 21st. Jefferies Financial Group lifted their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a buy rating in a research report on Monday, May 20th. Finally, Morgan Stanley started coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They issued an overweight rating and a $40.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $43.11.

Dyne Therapeutics Stock Down 1.0 %

Shares of NASDAQ:DYN opened at $41.54 on Tuesday. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $42.56. The stock has a market cap of $3.63 billion, a PE ratio of -10.46 and a beta of 1.07. The business has a 50 day moving average of $32.30 and a 200-day moving average of $26.22.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.81). Equities research analysts expect that Dyne Therapeutics will post -3 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, COO Susanna Gatti High sold 2,738 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $77,403.26. Following the completion of the transaction, the chief operating officer now directly owns 154,062 shares in the company, valued at $4,355,332.74. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 2,588 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $28.27, for a total transaction of $73,162.76. Following the sale, the senior vice president now owns 116,695 shares of the company’s stock, valued at $3,298,967.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Susanna Gatti High sold 2,738 shares of the business’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26. Following the sale, the chief operating officer now directly owns 154,062 shares in the company, valued at approximately $4,355,332.74. The disclosure for this sale can be found here. Insiders sold a total of 202,133 shares of company stock worth $6,500,387 over the last three months. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DYN. SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics in the second quarter worth $217,000. DekaBank Deutsche Girozentrale grew its stake in shares of Dyne Therapeutics by 50.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the company’s stock worth $1,710,000 after purchasing an additional 20,000 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Dyne Therapeutics in the first quarter worth $140,666,000. Artal Group S.A. grew its stake in shares of Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Dyne Therapeutics by 29.9% in the first quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock worth $1,271,000 after purchasing an additional 10,317 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.